Diffuse large B cell lymphoma (DLBCL) is a malignant
tumor derived from mature B
cells. Currently,
chemotherapy is still the main clinical
treatment. However, some
patients experience
recurrence or refractory conditions
after treatment. On June 15, 2023, the FDA approved the
marketing of glofitamab, a CD3/CD20 bispecific
monoclonal antibody, to provide the new
treatment plan for
patients with recurrent or refractory DLBCL after receiving 2-line or above systemic
treatment. This article reviews pharmacological effects, clinical studies,
safety, usage and
dosage of glofitamab. Glofitamab mainly
plays a
therapeutic role in DLBCL by promoting the activation and proliferation of
T cells,activating
T cells to release
tumor cell-
killing proteins, and
mediating the lysis of B
cells. Clinical studies have shown that glofitamab has a better complete and objective response rate for recurrent or refractory DLBCL. Common adverse reactions caused by glofitamab include mild/moderate
cytokine release syndrome,
musculoskeletal pain,
rash,
fatigue, and so on,without significant
drug interactions.